The management of idiopathic pulmonary fibrosis (IPF) has evolved from supportive care alone to disease-modifying therapy aimed at slowing disease progression. Current evidence supports early initiation of antifibrotic treatment to preserve lung function and improve long-term outcomes. Here is a quick question on the contemporary management of idiopathic pulmonary fibrosis! (Scroll down to answer the question) ##Reference## Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med.…
